LDP-CDP1 (NCT04739111) Exploratory Clinical Trial

AKA: NCT04739111 Clinical Trial, An Exploratory Clinical Study of LDP Combined With CDP1 in Patients with Advanced Malignant Tumor.
Context:
- Clinical Trial Website: https://clinicaltrials.gov/ct2/show/NCT04739111
- it is an open, dose-escalation and dose-extension exploratory clinical trial.
Example(s):
- …
Counter-Example(s):
- ISRCTN31235821 Clinical Trial,
- UMIN000027449 Clinical Trial,
See: National Clinical Trial (NCT) Number, Clinical Trial, Decentralized Clinical Trial, Adaptive Clinical Trial, Confirmatory Clinical Trial, Pragmatic Clinical Trial, Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1), Human Anti-PD-L1 Monoclonal Antibody Injection (LDP).

References

(ClinicalTrials.gov, 2021) ⇒ https://clinicaltrials.gov/ct2/show/NCT04739111 Last Update Posted: February 8, 2021.
- QUOTE: This is an open, dose-escalation and dose-extension exploratory clinical study for patients with advanced malignancy who have failed standard therapy. In the dose-escalation phase, a fixed dose of CDP1 will be given once a week, while LDP will be given every two weeks with dose climbing. Then, cohort studies (cohorts 1 to 5) will be conducted during the dose-expansion phase. The purpose is to preliminarily evaluate the safety and efficacy of LDP combined with CDP1 in the treatment of patients with advanced malignant tumor, and to determine the recommended dose for clinical trial.